Literature DB >> 9404956

Hepatitis G virus infection before and after liver transplantation. Liver Transplantation Database.

J H Hoofnagle1, M Lombardero, Y Wei, J Everhart, R Wiesner, R Zetterman, A J Yun, L Yang, J P Kim.   

Abstract

The hepatitis G virus is a newly discovered flavivirus that has been linked to acute and chronic hepatitis of unknown cause. We determined the prevalence of hepatitis G virus infection in 179 selected patients undergoing liver transplantation at three centers participating in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Transplantation Database. Pretransplantation and posttransplantation specimens were tested for hepatitis G virus RNA by polymerase chain reaction. Before transplantation, 9 of 38 (24%) patients with fulminant hepatic failure, 9 of 62 (15%) with cryptogenic cirrhosis, 3 of 35 (9%) with cholestatic liver disease, and 5 of 44 (11%) with chronic hepatitis C were positive for hepatitis G virus RNA (P = .27). Patients with and without viral RNA were similar in clinical features, liver test abnormalities, and survival after transplantation. Posttransplantation serum specimens were tested from 73 patients; 9 of 11 (82%) who were positive for viral RNA before transplantation remained positive, but 35 of 62 (56%) patients who were initially negative became positive after transplantation, a rate consistent with that predicted from the number of blood products administered. Only 5% of de novo HGV infections could be attributed to preexisting hepatitis G virus RNA in the donor. Comparison of patients with and without hepatitis G virus infection showed no difference in incidence of hepatitis after transplantation. Thus, hepatitis G virus infection was present in 15% of patients before and appeared de novo in half of patients after liver transplantation. Although hepatitis G virus infection was not associated with poor outcome, the frequency of this infection after transplantation calls for further long-term evaluation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9404956     DOI: 10.1002/lt.500030604

Source DB:  PubMed          Journal:  Liver Transpl Surg        ISSN: 1074-3022


  4 in total

Review 1.  Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies.

Authors:  H M Chapel
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

2.  Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.

Authors:  Xiuying Liu; Yibing Huang; Min Cheng; Ling Pan; Youhui Si; Guirong Li; Yuqiang Niu; Lianjing Zhao; Jin Zhao; Xiang Li; Yuxin Chen; Wei Yang
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

Review 3.  Hepatitis G virus.

Authors:  Vasiliy Ivanovich Reshetnyak; Tatiana Igorevna Karlovich; Ljudmila Urievna Ilchenko
Journal:  World J Gastroenterol       Date:  2008-08-14       Impact factor: 5.742

Review 4.  Human pegivirus infection after transplant: Is there an impact?

Authors:  Anna Mrzljak; Bojana Simunov; Ivan Balen; Zeljka Jurekovic; Tatjana Vilibic-Cavlek
Journal:  World J Transplant       Date:  2022-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.